Cancer Medicines Outcomes Programme Public Health Scotland (CMOP-PHS) report for the Scottish Medicines Consortium (SMC)
First-line immune-checkpoint inhibitors with or without chemotherapy for metastatic non-small cell lung cancer: SMC2906

About this release

This release by Public Health Scotland (PHS) uses information from the National SACT Dataset.

This work was requested by the Scottish Medicines Consortium (SMC) to support their decision-making processes. Cemiplimab in combination with platinum‐based chemotherapy for the first‐line treatment of adult patients with non-small cell lung cancer (NSCLC), expressing programmed death-ligand 1 (PD-L1) (in ≥ 1% of tumour cells), with no epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK) or reactive oxygen species-1 (ROS1) aberrations, who have: 1. Locally advanced NSCLC who are not candidates for definitive chemoradiation or 2. metastatic NSCLC, is being assessed for use in Scotland (SMC2906).

The aim of this work was to capture real-world evidence (RWE) from Scotland on the use of immune checkpoint inhibitors (ICI) for adults with metastatic NSCLC. Details of the presumptions made to identify this cohort are described in Section 2.3.1 of the main report. This work will enable SMC members to assess the relevance of information, provided as part of the assessment process for SMC2906, to patients in Scotland.

The objectives were to:

• Determine the number of patients receiving first-line ICI with or without chemotherapy for metastatic NSCLC (with no EGFR, ALK and ROS mutations).
• Describe the baseline characteristics of patients receiving first-line ICI with or without chemotherapy for metastatic NSCLC (with no EGFR, ALK and ROS mutations).